The Journal Of Clinical And Aesthetic Dermatology[JOURNAL]
Sun
200 papers
What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.
Childs BA, Merola JF
J Clin Aesthet Dermatol · 2026 Jan · PMID 41648089
OBJECTIVE: We aim to review current treatment strategies for cutaneous lupus erythematosus (CLE) and highlight emerging therapies, evolving outcome measures, and practical considerations that may inform future management...
OBJECTIVE: We aim to review current treatment strategies for cutaneous lupus erythematosus (CLE) and highlight emerging therapies, evolving outcome measures, and practical considerations that may inform future management of this clinically heterogeneous disease. METHODS: We conducted a narrative review of the literature using PubMed to identify relevant clinical trials, observational studies, and mechanistic investigations related to CLE treatment. Emphasis was placed on studies published within the past 15 years. Expert opinion from dermatology and rheumatology was incorporated to contextualize evolving therapies and their application in clinical practice. RESULTS: Current management of CLE follows a stepwise framework, with antimalarials and immunosuppressants forming the foundation of systemic therapy. However, many patients experience refractory disease, especially in chronic or hypertrophic subtypes. Advances in the understanding of CLE pathogenesis have led to the development of targeted biologics and small molecule agents that modulate Type I interferon signaling, B- and T-cell activation, and inflammatory cytokine pathways. Novel tools such as Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) and the Investigator Global Assessment for Cutaneous Lupus (CLA-IGA-R) are being validated to standardize disease assessment, while RNA tape sampling and real-world electronic health record (EHR)-based algorithms are enhancing research precision. Emerging therapies, such as belimumab, anifrolumab, litifilimab, deucravacitinib, and enpatoran, demonstrate promise in both clinical trials and real-world settings. LIMITATIONS: As a narrative review, this study is limited by the lack of systematic inclusion criteria and formal quality assessment of individual studies. CONCLUSION: Ongoing therapeutic innovation, guided by mechanistic insights and strengthened by the development of standardized outcome measures, is transforming the CLE landscape and advancing the goal of precision-based, durable disease control.
The Application of a Formulation Containing Hydroxypropyl Tetrahydropyrantriol and Niacinamide to Augment Anti-aging Benefits in a Double-blind, Randomized Nonablative Laser Treatment Study.
Ablon G, Paturi J, Juchaux F … +11 more , Barresi-Thornton R, Fallou B, Liao IC, Yan J, Chen Y, Laboureau J, Ballihaut C, Catalan Martin E, Simonnet JT, Marat X, Zheng Q
J Clin Aesthet Dermatol · 2025 Dec · PMID 41647767
OBJECTIVE: With advances in aesthetic procedures, best practices for postprocedure care to support immediate healing and augment efficacy are still without consensus. A postprocedure formula containing hydroxypropyl tetr...
OBJECTIVE: With advances in aesthetic procedures, best practices for postprocedure care to support immediate healing and augment efficacy are still without consensus. A postprocedure formula containing hydroxypropyl tetrahydropyrantriol (HPT) and niacinamide (NAM) has been developed. This study evaluated the functional benefits and clinical efficacy of pairing HPT/NAM formula with nonablative fractional laser treatment. METHODS: The functional benefits of HPT/NAM were explored using 2D cellular models, reconstructed skin equivalents, and ex vivo skin models. The clinical efficacy of a HPT/NAM formula vs. a clinical control (Aquaphor Healing Ointment) was investigated through a randomized, double-blind, split-face, multicenter, multiethnic study with a White and a Northeast Asian panel. The investigative products were randomly assigned to one side of the face following a single full-face fractional nonablative laser procedure, and the products were applied twice daily for 56 days. RESULTS: In vitro testing showed that the HPT/NAM combination decreased the secretion of prostaglandin E2 (PGE2), encouraged the production of glycosaminoglycan, α-smooth muscle actin, and various angiogenic growth factors. In both panels, the HPT/NAM formula demonstrated significant improvement vs. the clinical control for key anti-aging parameters such as fine lines, crow's feet wrinkles, skin roughness, and overall healthy appearance over the course of 56 days. LIMITATIONS: This study only investigated the pairing of HPT/NAM formula with nonablative laser treatment. CONCLUSION: This study demonstrated comparable healing benefits to the clinical control along with augmented skin resurfacing benefits with HPT/NAM use following a nonablative fractional laser treatment.
A Review of The Efficacy of Complementary and Alternative Medicines in Managing Dermatologic Infectious Diseases.
Ufomadu P, Gill BJ, Shimizu I … +2 more , Orengo I, Rosen T
J Clin Aesthet Dermatol · 2025 Dec · PMID 41647766
Dermatologic infections, particularly fungal and viral, are globally prevalent and often lead patients to seek complementary and alternative medicines (CAMs). This review critically evaluates 17 studies investigating CAM...
Dermatologic infections, particularly fungal and viral, are globally prevalent and often lead patients to seek complementary and alternative medicines (CAMs). This review critically evaluates 17 studies investigating CAM efficacy in treating dermatologic infectious diseases, focusing on those evaluated in randomized controlled trials (RCTs). Tea tree oil shows modest benefit for fungal infections such as tinea pedis and onychomycosis, though studies are limited by poor blinding and dropout rates. For herpes simplex virus (HSV), propolis and demonstrate potential antiviral effects, but findings are limited by subjective outcomes and industry sponsorship. Green tea extract (polyphenon E) shows efficacy in treating genital warts, though adverse skin reactions and publication bias warrant caution. Other agents, including garlic-derived ajoene, honey mixtures, and podophyllin, show promise but lack robust RCT validation. While CAMs offer intriguing therapeutic avenues, rigorous trials with standardized outcomes are essential to guide evidence-based integration into dermatologic care and improve patient-centered treatment strategies.
PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.
Chau CA, Baldwin HE, Del Rosso JQ … +9 more , Harper JC, Lain E, Schlesinger T, Shahbaz A, Woolery-Lloyd H, Jaworski JC, Seal MS, Hanna D, Lio P
J Clin Aesthet Dermatol · 2025 Dec · PMID 41647765
Many inflammatory skin conditions share mechanistic pathways involving multiple receptors and cytokines. Perhaps there is no better endorsement of this idea than the foundational concept of "steroid-responsive dermatoses...
Many inflammatory skin conditions share mechanistic pathways involving multiple receptors and cytokines. Perhaps there is no better endorsement of this idea than the foundational concept of "steroid-responsive dermatoses." Similarly, targeting the phosphodiesterase 4 (PDE4) enzyme, which exists at the crux of several pathways that contribute to inflammatory skin diseases, offers an avenue by which the pathogenesis of multiple conditions may be interrupted. This suggests that PDE4 inhibitors may assume a similar complementary framework for treating "PDE4 inhibitor-responsive dermatoses." Certain formulations of PDE4 inhibitors (including apremilast, crisaborole, and roflumilast) have undergone rigorous investigation in clinical trials and demonstrated robust efficacy and safety in many dermatologic conditions, achieving United States Food and Drug Administration approval for atopic dermatitis, psoriasis, and seborrheic dermatitis. Herein, we summarize the clinical evidence supporting the emerging concept of "PDE4 inhibitor-responsive dermatoses" and propose that PDE4 inhibition offers an additional pathway to achieving desired clinical outcomes.
Durability of Conventional Immunosuppressants in the Treatment of Oral Lichen Planus.
Seifert RM, Noot CH, Issa NT … +6 more , Hull CM, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hopkins ZH
J Clin Aesthet Dermatol · 2025 Dec · PMID 41647764
BACKGROUND: Oral lichen planus (OLP) is an inflammatory disease involving the oral mucosa. It affects roughly 0.5% to 2% of the global population and has an associated risk of oral squamous cell carcinoma. Treatment of m...
BACKGROUND: Oral lichen planus (OLP) is an inflammatory disease involving the oral mucosa. It affects roughly 0.5% to 2% of the global population and has an associated risk of oral squamous cell carcinoma. Treatment of moderate to severe OLP often requires immunosuppression. The durability of immunosuppressive medication is currently unknown and is important for understanding therapeutic testing needs. OBJECTIVE: We investigated traditional immunosuppressive drug survival in patients with OLP and evaluated potential discontinuation factors. METHODS: We retrospectively analyzed patients with OLP treated with methotrexate, mycophenolate, azathioprine, or cyclosporine. Time to medication discontinuation was evaluated using the Kaplan-Meier estimator, and Cox proportional hazards regression was used to compare the risk of discontinuing a medication between medications and across patient demographic and disease factors. RESULTS: We identified 125 treatment periods with mycophenolate (n=58), methotrexate (n=34), azathioprine (n=19), or cyclosporine (n=14). Most patients had erosive disease (92%), and median time (IQR) to discontinuation due to adverse events or inefficacy was 9.43 months (6.51-16.1). Overall, only cyclosporine was associated with higher risk of discontinuation compared to methotrexate (hazard ratio [HR]: 2.94; 95% confidence interval [CI]: 1.32-6.45). There was no evidence for risk differences across age or sex for the overall cohort. Within individual medication groups, age was associated with a small increased risk of discontinuing mycophenolate (HR: 1.05; 95% CI: 1.00-1.10) and a small decreased risk in cyclosporine (HR=0.94, 95% CI: 0.89-0.99). Otherwise, no demographic factors were associated with discontinuation. Treatment success was reported 8 times. DISCUSSION: Immunosuppressive medications were frequently discontinued after short time periods, and few were discontinued due to success. These data highlight the need for better systemic therapy in OLP.
Laser-assisted Analgesic and Vasoconstrictive Drug Delivery During and After Fractional CO Resurfacing: A Novel Technique to Enhance Procedural Tolerance and Recovery.
Ali I, Ceilley R, Smythe C
J Clin Aesthet Dermatol · 2025 Dec · PMID 41647763
BACKGROUND: Fractional carbon dioxide (CO) laser resurfacing is an effective treatment of various dermatological conditions. Pain, erythema, and edema following fractional ablative resurfacing are key limitations to pati...
BACKGROUND: Fractional carbon dioxide (CO) laser resurfacing is an effective treatment of various dermatological conditions. Pain, erythema, and edema following fractional ablative resurfacing are key limitations to patient comfort and satisfaction. OBJECTIVE: This study aims to describe a novel technique using laser-assisted drug delivery to administer a combination of local anesthetics and epinephrine both during and after fractional CO laser resurfacing, enhancing procedural anesthesia and postprocedure recovery. METHODS: We performed an observational review of patient-reported pain scores and clinical outcomes in patients treated with application of an anesthetic spray during and after fractional CO laser resurfacing treatments. RESULTS: Patients demonstrated an average of 68% reduction in pain scores (<0.001) scores postapplication, with additional clinical improvements in postlaser erythema and edema. CONCLUSION: Laser-assisted drug delivery of local anesthetics and epinephrine after fractional ablative resurfacing appears to offer a simple, low-cost adjunct for improving patient experience and recovery. Further investigation is warranted.
Alopecia Areata in Skin of Color.
Sangha AM
J Clin Aesthet Dermatol · 2025 · PMID 41647049
Abstract loading — click title to view on PubMed.
Perceptual Congruence.
Robertson LJ, Ciccarelli JC
J Clin Aesthet Dermatol · 2025 · PMID 41647048
This article explores the concept of perceptual congruence, the alignment between an individual's internal self-image and their external appearance, and its impact on self-esteem and wellbeing. It discusses how self-perc...
This article explores the concept of perceptual congruence, the alignment between an individual's internal self-image and their external appearance, and its impact on self-esteem and wellbeing. It discusses how self-perception is shaped by internal and external factors, including the influence of social media and cultural beauty standards. The article argues that aesthetic procedures can address perceptual incongruence by helping individuals achieve a closer match between their perceived and idealized selves, leading to enhanced self-regard and improved mental health outcomes.
Clinical Age-reversal Quantification of a Facial Skincare Regimen with Sirtuin-targeting Ingredients in a Multiethnic Population.
Bruning E, Lain ET, Ablon G … +7 more , Bucay V, Burgess C, Del Rosso J, Farris PK, Waibel J, DiCanio D, Vickery S
J Clin Aesthet Dermatol · 2025 Dec · PMID 41640789
BACKGROUND: Efficacy evaluations of topical cosmetic products purported to produce younger-appearing skin require an objective assessment of perceived age. The aim of this study is to quantify the age-reversal efficacy o...
BACKGROUND: Efficacy evaluations of topical cosmetic products purported to produce younger-appearing skin require an objective assessment of perceived age. The aim of this study is to quantify the age-reversal efficacy of a facial skincare regimen containing sirtuin-targeting and other anti-aging ingredients in a multiethnic population in terms of change in perceived age, using a validated age prediction model. METHODS: In this single-center, monadic study, eligible participants (n=72) applied a 3-product regimen (serum, soft crème, and eye crème) twice daily for 12 weeks. High-resolution digital photographs of subjects were graded for 7 facial parameters using an 11-point photonumeric scale (0=no signs of aging; 10=severe signs of aging) at baseline and 2, 4, 6, 8, and 12 weeks. Predicted Age scores derived from the model algorithm at each assessment point were compared with baseline scores to calculate change in Predicted Age in years. RESULTS: Statistically significant decreases vs. baseline in calculated Predicted Age were observed as early as Week 2, with the difference increasing with continued product application (difference at Week 12 was -4.0 years). Each facial aging parameter improved at a different rate, with forehead lines and elongated cheek pores significantly improving as early as Week 2. Under eye lines and forehead lines showed the greatest calculated improvement over time. CONCLUSION: Based on the Predicted Age model, the 3-product face/eye skincare regimen applied twice daily resulted in a significant decrease in calculated Predicted Age starting as early as 2 weeks, with continued improvement over time, and a decrease of 4.0 years by Week 12.
Laser Hair Reduction to the Residuum Improves Quality of Life in People with Amputations.
Diong S, Gallagher C, Clowry J … +2 more , Irvine AD, McAleer MA
J Clin Aesthet Dermatol · 2025 Dec · PMID 41640788
People with amputations using limb prosthetics commonly develop dermatologic complications, such as impaired skin integrity and folliculitis, at the residuum-prosthesis interface (RPI). Dermatologic complications are the...
People with amputations using limb prosthetics commonly develop dermatologic complications, such as impaired skin integrity and folliculitis, at the residuum-prosthesis interface (RPI). Dermatologic complications are the primary cause of dissatisfaction with prosthetics, hindering rehabilitation and leading to prosthesis abandonment. This has a deleterious impact on health-related quality of life (HRQOL). Positive outcomes have been associated with laser hair reduction (LHR) for those with traumatic lower limb amputations; however, this has not been studied in those with upper limb amputations or amputations due to other conditions. We performed a prospective study to assess the effects of skin conditions at the RPI on HRQOL and determine the potential benefit from LHR. Four patients were identified: 75% (n=3) with lower-limb amputations and 25% (n=1) with upper limb amputations. Amputation indications included infection (25%, n=1), congenital malformations (25%, n=1) and trauma (50%, n=2). Participants received 6 sessions of LHR, either alexandrite 755nm alone or in combination with Nd:YAG 1064nm laser. The Skindex-16 survey was performed along with 7 amputee-specific questions. Improvements in HRQOL were seen in all patients and subscales, with an overall average improvement of 50%. Functioning subscale improvement was greatest, at 60%. All patients (100%) were satisfied with LHR treatment. To our knowledge, this is the first study to examine the impact of LHR on the HRQOL of people with upper and lower limb prostheses. LHR is a minimally invasive technique to treat and prevent common dermatologic complications of the RPI, promoting improved self-confidence and prosthesis fit. This study identified an important role for dermatologists to engage with this community to improve their functional capacity and quality of life.
Tattoo-related Uveitis: A Devastating and Fairly Common Association.
Navarrete-Martínez M, Macias-Rule AA, Orozco-Brizuela MA … +1 more , Contreras-Ruiz J
J Clin Aesthet Dermatol · 2025 Dec · PMID 41640787
Abstract loading — click title to view on PubMed.
Pearly Penile Papules: A Systematic Review of Treatment Modalities.
Friedmann DP, Martingano I, Ahmad N … +2 more , Tarbox MB, Verma KK
J Clin Aesthet Dermatol · 2025 Dec · PMID 41640786
OBJECTIVE: Because pearly penile papules (PPP) are common, asymptomatic, and benign lesions that are often cosmetically bothersome to patients, we sought to systematically review all available treatment options for PPP....
OBJECTIVE: Because pearly penile papules (PPP) are common, asymptomatic, and benign lesions that are often cosmetically bothersome to patients, we sought to systematically review all available treatment options for PPP. METHODS: PubMed, Scopus, Embase, and Cochrane databases were queried with relevant terms, with all articles describing treatment modalities for PPP included in this review. Articles related to PPP but lacking treatment information or without novel clinical or patient data, unrelated to PPP, or not available in English were excluded. RESULTS: The database query yielded 254 unique articles. After screening and evaluation for duplicates and inclusion and exclusion criteria, 17 publications, all of which were retrospective case reports or case series, with 142 patients were included and analyzed. The most common modality used was ablative laser (10 articles), eight of which involved carbon dioxide laser, as well as erbium yttrium-aluminum-garnet (YAG) and holmium:YAG lasers. Liquid nitrogen (3 articles) and single reports of pulsed dye laser, nonablative 1550nm fractional laser resurfacing, and electrocoagulation with or without 30% trichloroacetic acid peel were also found. Most articles reported complete lesion removal and high patient satisfaction with no reports of infection or scarring. LIMITATIONS: This review is primarily limited by publication bias, with variable or limited methods of reporting efficacy/response and adverse event data. CONCLUSION: Multiple modalities can achieve safe and effective treatment of PPP with high patient and provider satisfaction.
Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel.
Rosenberg AL, Shah M, Del Rosso JQ … +11 more , Baldwin H, Harper J, Hebert AA, Keri J, Kwong P, Rieder E, Gold LS, Bartley B, Burshtein J, DeBusk L, Zakria D
J Clin Aesthet Dermatol · 2025 Dec · PMID 41640785
BACKGROUND: The purpose of this meeting was for an expert panel to analyze current literature and provide updated consensus statements regarding the optimal management, safety, and efficacy of oral antibiotics in acne vu...
BACKGROUND: The purpose of this meeting was for an expert panel to analyze current literature and provide updated consensus statements regarding the optimal management, safety, and efficacy of oral antibiotics in acne vulgaris (AV). METHODS: A thorough literature search was conducted across PubMed, Scopus, and Google Scholar to identify English-language original research articles evaluating the use of oral antibiotics for AV. An expert panel of 8 dermatologists, specializing in the management of AV, convened to assess the findings and develop statements regarding oral antibiotics for AV. Each statement was approved through a modified Delphi process, and a strength of recommendation was assigned based on the Strength of Recommendation Taxonomy (SORT) criteria. RESULTS: A total of 544 articles regarding the safety, efficacy, and management of oral antibiotics for AV were identified through the literature search. Following a rigorous screening process, 17 articles were deemed relevant to the research questions and provided to the panelists for review prior to the roundtable discussion. The panel reached unanimous agreement on 10 consensus statements and recommendations, assigning seven a strength of A, one a strength of B, and two a strength of C. CONCLUSION: The expert panel concluded that oral antibiotics can be used in the treatment of moderate-to-severe AV, oral antibiotics should be combined with topical treatments, and duration of use should be determined based on individualized patient care. Tetracyclines are recognized options for AV therapy, with sarecycline considered a preferred option for AV due to its targeted mode of action, unique ribosomal binding properties, narrow spectrum of antibiotic activity, lower bacterial resistance risk, and overall better tolerability. Additionally, tetracyclines should be avoided in pregnancy and in young children.
Selected Abstracts from Elevate-Derm Summer Conference 2025.
J Clin Aesthet Dermatol · 2025 · PMID 41502958
Abstract loading — click title to view on PubMed.
A Unique Case of Squamous Cell Carcinoma on the Palm in a Patient with Lyme Disease.
Mukarram M, Rashid Z, Shuker S
J Clin Aesthet Dermatol · 2025 · PMID 41498020
Squamous cell carcinoma (SCC) is the second most common type of skin cancer following basal cell carcinoma (BCC). Risk factors for the development of SCC include exposure to ultraviolet light (UV) and non-UV-related risk...
Squamous cell carcinoma (SCC) is the second most common type of skin cancer following basal cell carcinoma (BCC). Risk factors for the development of SCC include exposure to ultraviolet light (UV) and non-UV-related risk factors, such as chronic wounds, Marjolin ulcers, and human papillomavirus (HPV) infection. In this case report, we report an interesting case of the development of SCC in the palm of a patient with an extensive history of Lyme disease.
Cosibelimab: A Novel Therapeutic for Advanced Cutaneous Squamous Cell Carcinoma.
Burshtein J, Schlesinger T
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446722
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer worldwide. Treatments of locally advanced cSCC (laCSCC) and metastatic cSCC (mCSCC) have been evolving with the introduction of immunotherapi...
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer worldwide. Treatments of locally advanced cSCC (laCSCC) and metastatic cSCC (mCSCC) have been evolving with the introduction of immunotherapies, which target the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway. Recently, cosibelimab was the first PD-L1 antibody approved by the United States Food and Drug Administration for the treatment of patients with laCSCC or mCSCC who are not candidates for curative surgery or radiation. Cosibelimab not only offers blockade of PD-L1 but also induces antibody-dependent cellular cytotoxicity. In its pivotal clinical trial, the objective response rate for patients with mCSCC treated with cosibelimab was 47.4%. Due to the different mechanisms of action, differences have been noted in the safety between PD-1 inhibitors and PD-L1 inhibitors, with PD-L1 inhibitors having a lower occurrence of Grade 3 or higher treatment-related adverse events, including immune-related adverse events. Additional real-world studies are needed to further evaluate its efficacy and safety. Cosibelimab is a novel immune checkpoint inhibitor and represents a promising therapeutic option for patients with advanced cSCC.
Nonmelanoma Skin Cancer in South Florida: A Change in the Relative Incidence of Basal and Squamous Cell Carcinoma.
Vanaria RJ, Chaudry A, Nestor MS
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446721
OBJECTIVE: Ultraviolet (UV) radiation is a major cause of nonmelanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Due to its demographics and geographic location, Florida's...
OBJECTIVE: Ultraviolet (UV) radiation is a major cause of nonmelanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Due to its demographics and geographic location, Florida's population is at increased risk of NMSC. While historical epidemiology suggests BCC has a significantly greater incidence than SCC, a 2012 study in South Florida reported a reverse in this ratio, with significantly higher SCC rates, warranting further investigation. METHODS: A South Florida dermatology database was analyzed for confirmed NMSC biopsy results from 2024. Lesions were categorized into BCC (superficial and nonsuperficial subtypes) and SCC (in situ SCC [isSCC] and invasive subtypes). RESULTS: Among 856 NMSC lesions, 247 (28.9%) were BCC and 609 (71.1%) were SCC. Subtypes included 54 superficial BCC (6.3%), 193 nonsuperficial BCC (22.5%), 268 isSCC (31.3%), and 341 invasive SCC (39.8%). DISCUSSION: These results align with earlier findings, contradicting the belief that BCC is the most common NMSC. SCC subtypes represented more than 70% of cases, suggesting a shift in incidence patterns. This trend may be linked to the early use of UV-B protection-dominant sunscreens, which offer less protection against UV-A, a significant factor in the development of SCC. Additionally, treating SCC-suspicious lesions as actinic keratoses in favor of biopsy for BCC-suspicious lesions may have contributed to prior findings. CONCLUSION: Our findings challenge traditional epidemiologic teachings, showing a higher incidence of SCC than BCC. These trends may reflect historical photoprotection and/or changing biopsy practices.
Analysis of Reddit Reveals Clascoterone Questions Among People with Acne.
Wang J, Patel P, Mineroff J … +1 more , Jagdeo J
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446720
OBJECTIVE: Patients with acne are increasingly using social media platforms such as Reddit to seek medical information. Skincare subreddits such as r/SkinCareAddiction, r/Skincare_Addiction, r/SkincareAddicts, and r/Acne...
OBJECTIVE: Patients with acne are increasingly using social media platforms such as Reddit to seek medical information. Skincare subreddits such as r/SkinCareAddiction, r/Skincare_Addiction, r/SkincareAddicts, and r/Acne have become important hubs of discussion for acne treatments, including the recently US Food and Drug Administration (FDA)-approved drug clascoterone (Winlevi). The objective of this study was to analyze questions and information needs of Reddit users with acne related to clascoterone. METHODS: The authors analyzed all clascoterone-related questions posted on the r/SkinCareAddiction, r/Skincare_Addiction, r/SkincareAddicts, and r/Acne subreddits. Questions were categorized and subcategorized for analysis. RESULTS: A total of 301 questions from 223 posts were analyzed. The largest proportion of questions were about concurrent use with other medical interventions or skincare regimens (25.9%) and adverse effects (17.3%). General experiences (14.0%) and usage instructions (12.0%) also made up a significant number of questions. LIMITATIONS: A limitation of this study is that Reddit users may not accurately represent the general population of patients with acne using clascoterone. CONCLUSION: This Reddit analysis of clascoterone therapy reveals key themes in questions and gaps in knowledge among people with acne that may not be readily apparent in clinical settings. This information can guide physicians to better address patient needs and improve patient outcomes.
Ethical Dilemmas in Clinical Dermatology: A Qualitative Analysis of American Academy of Dermatology Member Survey Responses.
Huang C, Sangari A, Sood A … +3 more , Balk R, Housholder AL, Stoff BK
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446719
OBJECTIVE: Dermatologists face multiple ethical challenges, but prior publications have studied these through case-based reporting. This study evaluates what ethical issues dermatologists find most pressing through a qua...
OBJECTIVE: Dermatologists face multiple ethical challenges, but prior publications have studied these through case-based reporting. This study evaluates what ethical issues dermatologists find most pressing through a qualitative analysis of open-ended survey responses from dermatologists. METHODS: We surveyed American Academy of Dermatology (AAD) members via email (n=3999) and asked respondents to describe, in one paragraph, a recent case or scenario that was ethically challenging in their practice of dermatology. Participants also answered multiple-choice questions about which types of ethical issues they found most challenging and common, as well as several other general queries about ethics in dermatology. We then conducted qualitative analysis on the free responses (n=188) and inductively found themes and subthemes. RESULTS: Ethical dilemmas faced by AAD members reflect numerous subthemes. The most reported ethical challenges were requests for insurance dishonesty, insurance barriers, unscheduled patients, overutilization of procedures, inappropriate medication or paperwork requests, and patient disrespect. To our knowledge, this study is the first to demonstrate the range of reported ethical challenges faced by dermatologists through qualitative analysis. LIMITATIONS: As a qualitative study, the results are not fully representative of all ethical issues faced in dermatology and do not quantify their prevalence. CONCLUSION: These results could direct future wider-scale, quantitative studies to gain further understanding of the ethical challenges dermatologists face and how those challenges may vary based on practice demographics. Wider ethical analysis, particularly of the financial aspects of modern dermatologic care, may benefit the dermatology workforce.
The Experiences of Black Dermatology Faculty in the United States.
Turner K, Hamid A, Barbosa V … +2 more , Taylor S, Elbuluk N
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446718
Abstract loading — click title to view on PubMed.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe